MARKET

EGRX

EGRX

Eagle Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

58.97
-0.58
-0.97%
After Hours: 58.97 0 0.00% 16:30 01/17 EST
OPEN
59.79
PREV CLOSE
59.55
HIGH
59.99
LOW
58.72
VOLUME
80.25K
TURNOVER
--
52 WEEK HIGH
64.94
52 WEEK LOW
38.38
MARKET CAP
806.09M
P/E (TTM)
33.11
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of EGRX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

EGRX News

  • Eagle Pharmaceuticals to Develop Dantrolene Sodium for Potential Treatment of Alzheimer’s Disease in Collaboration With University of Pennsylvania
  • Business Wire.6d ago
  • Tyme Technologies: Why Investors Should Be Bullish On The Eagle Partnership
  • Seeking Alpha - Article.6d ago
  • Tyme Initiates Dosing in Pivotal Pancreatic Cancer Study
  • Zacks.01/09 13:40
  • Eagle Pharma Reports Resubmission Of New Drug Application For RYANODEX For Exertional Heat Stroke
  • Benzinga.01/09 11:50

More

Industry

Pharmaceuticals
+0.13%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About EGRX

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin's lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
More

Webull offers Eagle Pharmaceuticals Inc (EGRX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.